TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 7951476
Drug: Smoking four
Normalized name: Four-Way
Approvals — FDA: no, EMA: no, PMDA: no
Description: Smoking four 0.8 mg cigarettes and ingesting 200 mg of caffeine
Study: 7951476
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg of caffeine (in non-smoking controls)
Study: 2889518
Drug: Amantadine 100
Normalized name: amantadine 100 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amantadine 100 mg bid
Study: 30635862
Drug: Linkage to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Linkage to care associated with treatment readiness
Study: 30635862
Drug: Linkage to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Linkage to care negatively associated with weekly alcohol consumption
Study: 21865768
Drug: Pure sodium
Normalized name: Dream Pure BB
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pure sodium glycerophosphate formulation (reference)
Study: 9764348
Drug: Heparin/Aspirin (H/A)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin/Aspirin (H/A) alone
Study: 9055693
Drug: Tetracycline solution
Normalized name: Tetracycline
DrugBank: Tetracycline (DB00759)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tetracycline solution conditioning for 5 minutes
Study: 9055693
Drug: Sterile saline
Normalized name: Aqua Care Sterile Saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sterile saline solution rinse
Study: 359904
Drug: Timolol ophthalmic
Normalized name: timolol ophthalmic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Timolol ophthalmic solution 0.25% and 0.5%
Study: 359904
Drug: Timolol alone
Normalized name: timolol
DrugBank: Timolol (DB00373)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Timolol alone or in combination with a topical cholinergic agent or/and a systemic carbonic anhydrase inhibitor
Study: 28917374
Drug: Bell pepper
Normalized name: Bell pepper
DrugBank: Green bell pepper (DB10556)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bell pepper juice (100 ml, twice/day) with integrated approach of yoga therapy (IAYT)
Study: 18503578
Drug: Integrated approach
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Integrated approach of yoga therapy (IAYT)
Study: 21953572
Drug: Tigecycline (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tigecycline (100 mg single dose) in subjects receiving hemodialysis
Study: 11738689
Drug: Placebo nasal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo nasal spray, administered once daily for 4 months.
Study: 9283509
Drug: Naltrexone (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naltrexone (50 mg/d)
Study: 29784554
Drug: Ibuprofen 600mg
Normalized name: IBUPROFEN 600MG TAB
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ibuprofen 600mg pre-event
Study: 27456464
Drug: Colla corii
Normalized name: CORID
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colla corii asini (CCA) 15 g
Study: 24981506
Drug: Adjuvant whole
Normalized name: Betula lenta whole
DrugBank: Betula lenta whole (DB14164)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant whole brain radiotherapy (WBRT) following local treatment of intracranial melanoma metastases
Study: 23053340
Drug: MicroPulse (MP)
Normalized name: 6 MP
DrugBank: Mercaptopurine (DB01033)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: MicroPulse (MP) treatment at the active leakage site guided by fluorescein angiography (n=16 eyes)
Study: 23053340
Drug: Intravitreal injection
Normalized name: Eylea 2 MG per 0.05 ML Intravitreal Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal injection of 1.25 mg Bevacizumab (BCZ) (n=10 eyes)
Study: 18344099
Drug: Oral administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration of fomepizole (15 mg/kg)
Study: 18344099
Drug: Intravenous administration
Normalized name: intravenous administration set
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous administration of fomepizole (15 mg/kg)
Study: 17148777
Drug: High-dose chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose chemotherapy with cyclophosphamide, thiotepa, and carboplatin (CTC group)
Study: 17148777
Drug: Standard-dose chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-dose chemotherapy with 5-fluorouracil, epirubicin, and cyclophosphamide (FEC group)
Study: 17148777
Drug: No systemic
Approvals — FDA: no, EMA: no, PMDA: no
Description: No systemic chemotherapy (no-CT group)
Study: 12663594
Drug: Thyroid function
Normalized name: Thyroid
DrugBank: Thyroid, porcine (DB09100)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thyroid function tests (TSH, thyroxine, triiodothyronine) annually and TPO antibodies every 4 years
Study: 3901660
Drug: ORS60 (Na+
Approvals — FDA: no, EMA: no, PMDA: no
Description: ORS60 (Na+ 60 mmol/l)
Study: 29084918
Drug: Ontuxizumab (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ontuxizumab (8 mg/kg) plus best supportive care
Study: 27353315
Drug: 8-session cue
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8-session cue exposure therapy
Study: 9646621
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg atorvastatin
Study: 8848472
Drug: NSAIDs (aspirin
Approvals — FDA: no, EMA: no, PMDA: no
Description: NSAIDs (aspirin and ibuprofen)
Study: 28390209
Drug: Control: biotène®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control: biotène® Gentle Mint Gel toothpaste (n = 77)
Study: 20713865
Drug: Rasburicase (0.20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rasburicase (0.20 mg/kg/d intravenously days 1‐5)
Study: 20713865
Drug: Rasburicase plus
Normalized name: Rasburicase
DrugBank: Rasburicase (DB00049)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Rasburicase plus allopurinol (rasburicase 0.20 mg/kg/d days 1 to 3 followed by oral allopurinol 300 mg/d days 3 to 5)
Study: 20713865
Drug: Allopurinol (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Allopurinol (300 mg/d orally days 1 to 5)
Study: 24965954
Drug: Oral health
Normalized name: CETYLPYRIDINIUM CHLORIDE 0.07 g in 100 mL ORAL RINSE [Assured Oral Health Fresh Mint]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral health care using an oral moisture gel
Study: 24965954
Drug: Standard oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard oral health care
Study: 20504306
Drug: Intradermal vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intradermal vaccine (15 microg HA/strain/0.1-ml dose)
Study: 6313458
Drug: Ranitidine, 150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine, 150 mg twice a day
Study: 7038142
Drug: Cytoreductive surgery
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cytoreductive surgery (nephrectomy) and adjuvant active immunotherapy (bacillus Calmette‐Guerin)
Study: 20810048
Drug: Interferon alpha
Normalized name: Interferon alpha-2a
DrugBank: Interferon alfa-2a (DB00034)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon alpha 2a (3 million units SC three times/week) + Ribavarin (1000 mg/day for weight ≤ 75kg; 1200 mg/day for weight > 75kg)
Study: 20810048
Drug: Interferon alpha
Normalized name: Interferon alpha-2a
DrugBank: Interferon alfa-2a (DB00034)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon alpha 2b (3 million units SC three times/week) + Ribavarin (1000 mg/day for weight ≤ 75kg; 1200 mg/day for weight > 75kg)
Study: 17469684
Drug: Clinical trials
Normalized name: DuoCare Clinical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clinical trials of pharmacotherapy for dementia
Study: 10414910
Drug: No G-CSF
Normalized name: G-CSF
DrugBank: Lenograstim (DB13144)
Approvals — FDA: no, EMA: no, PMDA: no
Description: No G-CSF (group A)
Study: 10414910
Drug: G-CSF administration
Normalized name: G-CSF
DrugBank: Lenograstim (DB13144)
Approvals — FDA: no, EMA: no, PMDA: no
Description: G-CSF administration (both early and delayed)
Study: 2221302
Drug: Continuous application
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous application of alfentanil (0.023 mg/kg b.w./h) and midazolam (0.10 mg/kg b.w./h)
Study: 30920339
Drug: CDP-choline (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: CDP-choline (500 mg) and galantamine (16 mg)
Study: 25532954
Drug: 400 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 μg capsaicin
Study: 25532954
Drug: 800 μg
Normalized name: hyaluronidase
DrugBank: Hyaluronidase (DB14740)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 800 μg capsaicin
Study: 25532954
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg ASA
Study: 25532954
Drug: 400 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 μg capsaicin + 500 mg ASA
Study: 25532954
Drug: 800 μg
Normalized name: hyaluronidase
DrugBank: Hyaluronidase (DB14740)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 800 μg capsaicin + 500 mg ASA
Study: 9756018
Drug: Systemic chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systemic chemotherapy with mitomycin, mitoxanthrone and cisplatin (5 patients)
Study: 9756018
Drug: Celiac axis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Celiac axis infusion regional chemotherapy with SpherexR microembolization (9 patients)
Study: 8147340
Drug: Immune milk
Normalized name: MILK
DrugBank: Cow milk (DB10543)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immune milk (90 g daily for 10 weeks)
Study: 22431578
Drug: Normokalemia (potassium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normokalemia (potassium 3.5-5.4 mmol/L)
Study: 22431578
Drug: Hyperkalemia (potassium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperkalemia (potassium >5.4 mmol/L)
Study: 11601016
Drug: Exogenous natural
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exogenous natural porcine pulmonary surfactant (150 mg/kg)
Study: 18048991
Drug: Miglitol administered
Normalized name: Miglitol
DrugBank: Miglitol (DB00491)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Miglitol administered in two divided doses: 25 mg just before a meal and 25 mg at 15 min after the start of a meal
Study: 16230541
Drug: Full-dose intraoperative
Normalized name: Rho(D) immune globulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Full-dose intraoperative radiotherapy with electrons (ELIOT)
Study: 8020670
Drug: Methotrexate (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methotrexate (15 mg/wk)
Study: 29620392
Drug: Cognitive‐behavioral therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive‐behavioral therapy (CBT)‐based guided self‐help (CBTgsh)
Study: 15336814
Drug: L-arginine enriched
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-arginine enriched cardioplegia and non-cardioplegic reperfusion
Study: 15336814
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no L-arginine)
Study: 11433695
Drug: Corticosteroid therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticosteroid therapy (oral prednisolone 40 mg/d for 1 month)
Study: 11433695
Drug: Various drug
Normalized name: VARIOUS DRUG CLASSES IN ATC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Various drug treatments (including corticosteroids, colchicine, propylthiouracil, etc.)
Study: 11433695
Drug: Monoclonal anti-TNFα
Normalized name: Anti-VEGF monoclonal antibody
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Monoclonal anti-TNFα antibodies
Study: 8459988
Drug: Ondansetron (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ondansetron (8 mg orally 3 times daily)
Study: 8459988
Drug: Ondansetron (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ondansetron (8 mg) and dexamethasone (8 mg) given orally
Study: 31092548
Drug: Low systemic
Normalized name: Dianeal Low Calcium 1.5 Intraperitoneal Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low systemic arterial compliance (SAC) defined as ≤0.64 mL/m²
Study: 22490854
Drug: Fluorouracil plasma
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fluorouracil plasma concentration <25 ng/ml
Study: 22490854
Drug: Fluorouracil plasma
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fluorouracil plasma concentration 25-35 ng/ml
Study: 22490854
Drug: Fluorouracil plasma
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fluorouracil plasma concentration >35 ng/ml
Study: 19403952
Drug: 7.5% maltodextrin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7.5% maltodextrin solution
Study: 17166184
Drug: Physiotherapy and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physiotherapy and steroid injection therapy combined
Study: 6405770
Drug: 9.2 mg
Normalized name: fusidate 49.2 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 9.2 mg of glyceryl trinitrate (GTN) cream (acute study)
Study: 6405770
Drug: 9.2 mg
Normalized name: fusidate 49.2 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 9.2 mg of glyceryl trinitrate (GTN) cream (1 h post-application)
Study: 6405770
Drug: 9.2 mg
Normalized name: fusidate 49.2 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 9.2 mg of glyceryl trinitrate (GTN) cream (chronic study)
Study: 6405770
Drug: Increased dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Increased dose of glyceryl trinitrate (GTN) cream (after 3 weeks)
Study: 6405770
Drug: Sublingual nitroglycerin
Normalized name: nitroglycerin Sublingual Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual nitroglycerin (during the study)
Study: 23412547
Drug: Humidification therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Humidification therapy (HUM)
Study: 8839294
Drug: Tridimensional Personality
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tridimensional Personality Questionnaire administered to social phobia patients
Study: 30945118
Drug: Oral semaglutide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral semaglutide 20 mg once daily (steady state) with lisinopril (20 mg single dose)
Study: 30945118
Drug: Oral semaglutide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral semaglutide 20 mg once daily (steady state) with warfarin (25 mg single dose)
Study: 30945118
Drug: Oral semaglutide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral semaglutide 20 mg once daily (steady state) with digoxin (500 μg single dose)
Study: 30945118
Drug: Oral semaglutide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral semaglutide 20 mg once daily (steady state) with metformin (850 mg twice daily for 4 days)
Study: 30945118
Drug: SNAC alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: SNAC alone (300 mg single dose) with lisinopril, warfarin, digoxin, or metformin
Study: 19092257
Drug: N-acetylcysteine (1,200
Approvals — FDA: no, EMA: no, PMDA: no
Description: N-acetylcysteine (1,200 mg/day)
Study: 15921686
Drug: Metformin pretreatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin pretreatment (1500 mg daily for 12 days, followed by clomiphene 150 mg daily for 5 days along with metformin)
Study: 8573554
Drug: Carbamazepine (CBZ)
Normalized name: Carbamazepine
DrugBank: Carbamazepine (DB00564)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Carbamazepine (CBZ) at a dose of 800 mg/day
Study: 28973164
Drug: Oral Glucose
Normalized name: glucose Oral Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Glucose Tolerance Test (OGTT)
Study: 29988707
Drug: Enhanced physiotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enhanced physiotherapy care package (education, twice daily coached breathing exercises for a minimum of 2 days, and 30 minutes of daily supervised early rehabilitation for a minimum of five postoperative days)
Study: 29988707
Drug: Standard care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard care physiotherapy (education, single session of coached breathing exercises, and daily early ambulation for 15 minutes)
Study: 26308708
Drug: Alfacalcidol at
Normalized name: alfacalcidol
DrugBank: Alfacalcidol (DB01436)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alfacalcidol at 1 μg/day
Study: 26308708
Drug: Alendronate 35
Normalized name: ALENDRONATE 35MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alendronate 35 mg/week
Study: 26308708
Drug: Commencement of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Commencement of glucocorticoid therapy
Study: 7829908
Drug: Fleroxacin 300
Normalized name: fleroxacin
DrugBank: Fleroxacin (DB04576)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fleroxacin 300 mg once a day for 3 days (cholera), 7 days (Salmonella enteritis), 5 days (other infectious enteritis)
Study: 29789908
Drug: Two-phasic contrast
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two-phasic contrast injection (25mgI/kg/s for 12 seconds in 1st phase and 3.0 ml/s for 7 seconds in 2nd phase) with two axial scans using smart-coverage technique.
Study: 29789908
Drug: Conventional protocol
Normalized name: Olay Professional Acne Protocol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional protocol with contrast injection (25mgI/kg/s for 14 seconds) and helical/axial scanning.
Study: 24176997
Drug: QVA149 110/50
Approvals — FDA: no, EMA: no, PMDA: no
Description: QVA149 110/50 μg
Study: 25222881
Drug: Glycopyrronium 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glycopyrronium 50 μg
Study: 22205617
Drug: roxatidine 75
Normalized name: roxatidine 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: roxatidine 75 mg
Study: 11901047
Drug: BG9719 alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: BG9719 alone (2 lower doses)
Study: 4050842
Drug: sublingual nifedipine
Normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: sublingual nifedipine
Study: 24177257
Drug: 3 months
Normalized name: TABLET, DOSE PACK, 3 MONTHS
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 months of dual antiplatelet therapy (aspirin 100-200 mg daily and clopidogrel 75 mg daily)
Study: 24177257
Drug: 12 months
Normalized name: Elecare HMO 0-12 Months
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12 months of dual antiplatelet therapy (aspirin 100-200 mg daily and clopidogrel 75 mg daily)
Study: 30463813
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg rosuvastatin
Study: 9787863
Drug: Remifentanil combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil combined with propofol (6 mg/kg/h)
Study: 6440383
Drug: Breast-conserving therapy
Normalized name: chicken breast preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Breast-conserving therapy
Study: 2502799
Drug: Intravenous m-chlorophenylpiperazine
Normalized name: m-phenylenediamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous m-chlorophenylpiperazine (0.1 mg/kg)
Study: 2502799
Drug: Oral m-chlorophenylpiperazine
Normalized name: Cleeravue-M Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral m-chlorophenylpiperazine (0.5 mg/kg)
Study: 782699
Drug: Methyl‐CCNU and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methyl‐CCNU and cyclophosphamide combination
Study: 23283356
Drug: Dexmedetomidine (0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine (0.4 µg/kg)
Study: 16713525
Drug: Complementary treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Complementary treatments (acupuncture and hypnotherapy)
Study: 12584861
Drug: Domestic bambuteral
Normalized name: domestic cow dander extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Domestic bambuteral tablet
Study: 12584861
Drug: Imported bambuteral
Normalized name: black imported fire ant allergenic extract
DrugBank: Solenopsis richteri (DB11026)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imported bambuteral tablet
Study: 3281308
Drug: Group 1:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group 1: '00' Dexon subcutaneous and '00' prolene subcuticular sutures
Study: 28399219
Drug: Multidisciplinary intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Multidisciplinary intervention targeting identified risk factors including physiotherapy, occupational therapy, geriatric assessment, optometry, and medication management
Study: 9059951
Drug: Nadolol (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nadolol (80 mg p.o. chronic therapy for 2 months)
Study: 8368985
Drug: Benadryl (diphenhydramine),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Benadryl (diphenhydramine), 50 mg
Study: 3126122
Drug: Growth-hormone releasing
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth-hormone releasing hormone (GHRH)
Study: 15301647
Drug: Panic Control
Normalized name: BENZALKONIUM CHLORIDE 1 g in 59 mL TOPICAL GEL [Donut Panic Hand Sanitizer]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Panic Control Therapy (PCT)
Study: 1315645
Drug: Arginine vasopressin
Normalized name: 1-deamino-8-D-arginine vasopressin
DrugBank: Desmopressin (DB00035)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Arginine vasopressin infusion (0.1 m‐units min‐1 kg‐1)
Study: 29426574
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of orthosis, nerve/tendon gliding exercises, and ultrasound therapy
Study: 19217019
Drug: Intravitreal ranibizumab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal ranibizumab (0.5 mg)
Study: 8983763
Drug: Cordaphene (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cordaphene (30 mg)
Study: 8983763
Drug: Diltiazeme (180
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diltiazeme (180 mg)
Study: 12742289
Drug: Calcium antagonists
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium antagonists (CAs)
Study: 2153475
Drug: Calcium chloride
Normalized name: Calcium Chloride
DrugBank: Calcium chloride (DB01164)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Calcium chloride (10 mg/kg bolus followed by 2 mg/kg/hr infusion)
Study: 30076173
Drug: Conventional front-line
Normalized name: Bos taurus frontal lobe preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional front-line induction chemotherapy (3+7 daunorubicin+cytarabine)
Study: 28628374
Drug: Multispecies probiotic
Normalized name: Rezyst Probiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multispecies probiotic supplement (GeriLact; n = 25)
Study: 28475373
Drug: Lurasidone 40
Normalized name: lurasidone 40 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lurasidone 40 mg/day
Study: 23421963
Drug: Lurasidone (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lurasidone (all doses)
Study: 17174639
Drug: Aspirin (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (50 mg) and dipyridamole / Placebo
Study: 12105162
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg allopurinol daily for 1 month
Study: 10337432
Drug: Emedastine 0.05%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Emedastine 0.05% ophthalmic solution
Study: 11158809
Drug: Ketorolac 0.5%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketorolac 0.5% ophthalmic solution